Nivagen Pharmaceuticals Acquired by PAI Pharma — Healthcare M&A

PAI Pharma has acquired Nivagen Pharmaceuticals, a pharmacy business in California, for $12 billion. Nivagen Pharmaceuticals manufactures sterile injectable products and expands ready-to-use (RTU) offerings for hospital accessibility, supporting healthcare M&A in the pharmacy sector. The private equity acquisition strengthens PAI Pharma acquisitions by adding domestic manufacturing capabilities and RTU product demand in CA acquisitions. The platform acquisition is announced and valued at over $100M, reflecting a private equity acquisition strategy to scale hospital-focused pharmaceutical supply.